To obtain the quantitative form corresponding to the full two-state model with the present formalism, we will calculate the fractional response, fresp = E/Emax, obtained as output of the transduction (amplification) function corresponding an input that is the fraction of activated receptors, fact, at a given ligand concentration [L] and use the parameter definitions to eliminate the unknown receptor concentrations. To recapitulate, in the present formalism, binding is characterized by the dissociation constant Kd that represents an ensemble average for all active and inactive forms:
Appendix 1. Derivation of the main equation for the present model and of its simplified forms
To obtain the quantitative form corresponding to the full two-state model with the present formalism, we will calculate the fractional response, fresp = E/Emax, obtained as output of the transduction (amplification) function corresponding an input that is the fraction of activated receptors, fact, at a given ligand concentration [L] and use the parameter definitions to eliminate the unknown receptor concentrations. To recapitulate, in the present formalism, binding is characterized by the dissociation constant Kd that represents an ensemble average for all active and inactive forms:
Ligand efficacy is characterized with a unitless ε parameter that represents the fraction of ligandbound receptors that are active:
In cases where constitutive activity is present (i.e., some fraction of the receptors can be active even in when not bound to a ligand), a baseline receptor efficacy (εR0) is defined in a similar manner (the fraction of unbound receptors that are active):
With these definitions, the fraction of activated receptors fact, which is proportional with the effect right after the receptor, can be expressed as a function of [L] :
Which after elimination of the receptor concentration terms results
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This, after an odds-ratio type transform
will serve as input for the present hyperbolic-type amplification function that uses γ = [Rtot]/Kγ as its parameter:
Introducing fact here and performing the corresponding algebraic transformations ) leads to the final general form for the present full (four-parameter) model:
For special cases of its parameters, this general form ( Figure 1A ) leads to simplified forms that can be used when adequate. For example, if there is no constitutive activity (no R* form), εR0 = 0, and this leads to the case and equation shown in Figure 1C (three parameter model as introduced earlier (Buchwald, 2017)):
On the other hand, if there is no amplification (or there is not enough data and a model with fewer parameters is needed), γ = 1, and this leads to the model shown in Figure 1B :
Further, if there is neither constitutive activity, εR0 = 0, nor signal amplification, γ = 1, both of the above forms collapse to a form corresponding to the Emax model of partial agonism ( Figure 1D ):
Finally, if there is no partial agonism (all occupied receptors are active), ε = 1, and this converts to the simple case of Clark equation ( Figure 1F ):
Supplementary Tables   Supplementary Table S1 . Parameters from fitting of data from Figure 9 (imidazoline-type α-adrenoceptor agonists; (Ruffolo et al., 1979) ) with the present model. All fittings were done with models implemented in GraphPad Prism, and in addition to the calculated parameters (shown with their calculated standard errors) descriptors of the quality of fit (correlation coefficient, r 2 , and sum of squared errors, SSE) are also included. a Experimental data, average of log KA (Table 3 ) and log KB (Table 4) from (Ruffolo et al., 1979) . b Derived values for the present model (using eq. 14). Table S2 . Parameters from fitting of data from Figure 10 (muscarinic agonists assessed at two different points after M3 receptor activation; (Sykes et al., 2009) ) with the present model. Simultaneous fit of two data sets (GTP, Ca) with the same set of Kd and ε parameters across all ligands could not be done in Prism, it was done in Microsoft Excel with the Solver tool after separate prefits to establish starting values. Other details are the same as in Table S1 . Supplementary Table S3 . Parameters from fitting of data from Figure 11 (dopamine receptor with and without irreversible inactivation using EEDQ; (Meller et al., 1987) ) with the present model. Details are the same as in Table S1 . Figure 12 (guinea-pig ileum contraction mediated by muscarinic receptor activation with carbachol and oxotremorine before and after inactivation; (Kenakin, 1993; Kenakin and Christopoulos, 2011) ) with the present model. Details are the same as in Table S1 . Supplementary Table S5 . Parameters from fitting of data from Figure 14 (opioids with wildtype µ-opioid receptor in the cAMP and β-arrestin2 assays; (Hothersall et al., 2017) ) with the present model and corresponding bias estimates. Details are the same as in Table S1 . Supplementary Table S6 . Parameters from fitting of data from Figure 15 (opioids in δ-and µ-opioid receptors -DOP and MOP, respectively; (Vezzi et al., 2013) ) with the present model. Details are the same as in Table S1 . Figure S1 . Chemical structure of some representative full agonist, partial agonist, and antagonist ligands for selected receptors as indicated. While maintaining important structural elements (pharmacophores) of the full agonists, partial agonists and antagonists also tend to incorporate additional building blocks often resulting in larger overall structures. Supplementary Figure S2 . Illustration of the effects of different amplification (γ) and efficacy parameters (εR0, ε) on the response of the present model (fully general form, eq. 16). Note that because of the interplay between ε and γ, the same response can be reproduced at different amplifications with a different set of εs and Kds (B vs. C). 
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